Physician profile
Thomas Lazzarini
NPI 1477088979
$14,730.68
in general payments reported to CMS, 2019-2025
13 companies · $11K in 2025
The $11K reported for 2025 was more than what 91% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2020: $172 · 2021: $456 · 2022: $2,178 · 2023: $659 · 2024: $533 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,957 · Food and Beverage: $2,667 · Travel and Lodging: $2,069.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,957.25 |
| Food and Beverage | $2,666.88 |
| Travel and Lodging | $2,068.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $7,873.73 | 2023-2025 | |
| Genentech USA, INC. | $2,464.99 | 2021-2025 | Vabysmo, Susvimo |
| Apellis Pharmaceuticals, INC. | $2,071.48 | 2024-2025 | Syfovre |
| Alcon Vision LLC | $800.08 | 2020-2023 | Constellation |
| Regeneron Healthcare Solutions, INC. | $482.27 | 2019-2025 | Eylea Hd |
| Astellas Pharma US INC | $444.77 | 2024-2025 | Izervay |
| Biotissue Holdings INC. | $130.74 | 2023 | |
| Oculus Surgical INC. | $116.54 | 2022 | |
| Ani Pharmaceuticals, INC. | $110.65 | 2024-2025 | Purified Cortrophin Gel |
| Regeneron Pharmaceuticals, INC. | $106.74 | 2023 | Eylea |
| Allergan, INC. | $83.70 | 2019 | |
| Genentech, INC. | $24.17 | 2024 | Vabysmo |
| Bausch & Lomb Americas INC. | $20.82 | 2024 | Xipere |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Lazzarini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.